Uncategorized

A combination of two chemotherapy drugs – gemcitabine and capecitabine – should be the new standard of care for pancreatic cancer patients who have had surgery to remove their tumour, according to a Cancer Research UK-funded study published in The Lancet. Experts say the combination should replace the standard treatment of giving patients gemcitabine alone following surgery. Twenty-nine per cent of patients given the drug combination lived for at least five years compared with only 16 per cent of patients given gemcitabine alone.

See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-01-25-study-establishes-new-standard-of-care-for-pancreatic-cancer-patients